NCT04634357 - ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2028

Conditions

HepatoblastomaHepatocellular Carcinoma (HCC)Liver NeoplasmsMetastatic Liver CancerLiver CancerHEMNOS

Interventions

DRUG

ET140203 T Cells

"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"

Trial Locations (2)

RECRUITING

UCSF Benioff Children's Hospitals, San Francisco

RECRUITING

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston